BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20201208T084500
DTEND;TZID=America/Los_Angeles:20201208T130000
DTSTAMP:20260423T033000
CREATED:20201204T011815Z
LAST-MODIFIED:20201204T011815Z
UID:1627-1607417100-1607432400@thebiocalendar.com
SUMMARY:PBSS Free Online Symposium: Preclinical Models to Guide Therapeutic Development in Oncology
DESCRIPTION:Day 1: December 08\, 2020 –   In Vivo Models and Case Studies with Targeted Therapeutics \nSymposium Overview and Relevance to Contemporary Issues in Development of Therapeutic Agents for Oncology (Mark Merchant\, Genentech)\nPreclinical Mouse Models for Oncology and Immuno-oncology Applications (Maryland Franklin\, Covance-Preclinical Oncology)\nPreclinical Development of AMG 510\, a First-in-human Covalent Inhibitor of KRASG12C for the Treatment of Advanced Solid Tumors (Karen Rex\, Amgen)\nPreclinical Investigation of NKTR-255\, a Polymer Conjugated IL-15 with Potent NK cell Activation and anti-tumor activity in combination with tumor targeting antibodies (Willem Overwijk\, Nektar Therapeutics)\nCase Study: Bench to Bedside with Immune Stimulating Antibody Conjugates (ISAC) (Shelley Ackerman\, Bolt Biotherapeutics) \nDay 2: December 15\, 2020- Models for CAR-T Therapy and Organoid Models \nSymposium Overview and Relevance to Contemporary Issues in Development of Therapeutic Agents for Oncology (Mark Merchant\, Genentech)\nAdvancing CAR T Cell Therapy for the Treatment of Solid Tumors (Saul Priceman\, City of Hope)\nThe Utility of Preclinical Models in Development of CAR T (John Langowski\, Kite Pharma)\nPatient-Derived Oganoids in Cancer Research: Biobanking\, Genome Engineering and Immune Cell Co-Cultures. (Yorick Post; formerly\, Clevers Lab of Hubrecht Institute; currently Surrozen)\nUse of Organoids in Cancer for Drug Screening\, Biomarker Development and Personalized Patient Therapy. (Philippe Depeille; UCSF)\nPatient-Derived and PDX-Derived Organoids for Oncology Drug Discovery (Dean Campbell\, Crown Biosciences)
URL:https://thebiocalendar.com/event/pbss-free-online-symposium-preclinical-models-to-guide-therapeutic-development-in-oncology/2020-12-08/
END:VEVENT
END:VCALENDAR